A T cell redirecting bispecific protein consisting of an affinity enhanced T cell receptor fused to an anti-CD3 molecule that engages gp100 presented by major histocompatibility complex class I HLA-A 02:01 on tumor cells.
For the treatment of metastatic uveal melanoma in patients positive for HLA-A02:01 with metastatic or unrespectable uveal melanoma.
It demonstrated superior overall survival and progression free survival compared with it Pembrolizumab, Ipilimumab, or dacarbazine.
Objective response rate was only 9% but the disease control rate was 46%, suggesting clinical benefit without substantial to reduction on imaging studies.
Associated with cytokine release syndrome, rash and requires in patient monitoring for the first three doses.
In a three-year efficacy and safety trial patients were treated withTebentafusp versus Pembrolizumab, ipilimumab or dacarbazine control.
At three years, 27% in theTebentafusp group survived and 18% in the control group.
Tebentafusp toxicity included rash and 83%, pyrexia, 76%, pus in 70%, and hypotension and 38%: only 2% of the treatment group discontinued therapy.